Concepedia

Alison L. Hannah

AL

70

Publications

6.9K

Citations

35

H-Index

1990

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

Dana-Farber Cancer Institute

University of California, San Francisco

Roswell Park Comprehensive Cancer Center

Alison L. Hannah is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pharmacotherapy.

Top concepts

Publications per year

1990–2022

70

Publications

70

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Jennifer K. Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine · 2018 · 2K citations · Full text

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Shanu Modi, Alison Stopeck, Hannah Linden et al. · Clinical Cancer Research · 2011 · 418 citations

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Shanu Modi, Alison Stopeck, Michael S. Gordon et al. · Journal of Clinical Oncology · 2007 · 331 citations

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Paul G. Richardson, Marcie Riches, Nancy A. Kernan et al. · Blood · 2016 · 317 citations · Full text

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.

Cheryl A. London, Alison L. Hannah, Regina Zadovoskaya et al. · PubMed · 2003 · 288 citations

, , +16

Rows per page

1–5 of 70